PRDS NASDAQ
Pardes Biosciences, Inc.
1W: +0.0%
1M: +3.4%
3M: +14.3%
1Y: -31.9%
$2.18
Last traded 2023-09-08 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$135.2M
52W Range0.75-3.67
Volume2,150,077
Avg Volume597,402
Beta0.42
Dividend—
Analyst Ratings
Company Info
CEOThomas G. Wiggans
Employees57
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-27
Websitepardesbio.com
2173 Salk Avenue
Carlsbad, CA 92008
US
Carlsbad, CA 92008
US
415 649 8758
About Pardes Biosciences, Inc.
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses. Its primary investigational therapy, PBI-0451, is currently progressing through clinical development with the aim of both treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their related health issues. Established in 2020, Pardes Biosciences maintains its corporate headquarters in Carlsbad, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tananbaum James B. | D-Return | 37,500 | $1.87 | 2023-08-31 |
| Tananbaum James B. | D-Return | 75,000 | $9.80 | 2023-08-31 |
| Tananbaum James B. | D-Return | 37,500 | $5.21 | 2023-08-31 |
| WIGGANS THOMAS G | U-Tender | 50,000 | $2.13 | 2023-08-31 |
| WIGGANS THOMAS G | D-Return | 562,500 | $2.08 | 2023-08-31 |